Chemical Industry News, Data & Insights
About Us
Sign in
Home
News
Topics
Sectors
Reports
Weekly
Analytics
Innovation and Product Development news
(page 3)
21 February 2026
Johnson & Johnson's TREMFYA® Shows Sustained Remission in Ulcerative Colitis Over 3 Years
TREMFYA® maintains clinical, endoscopic, and histologic outcomes in ulcerative colitis through 140 weeks, with high patient retention and no new safety concerns.
20 February 2026
Chugai Launches Japan's First Regenerative Treatment for Duchenne Muscular Dystrophy
ELEVIDYS, a one-time therapy for DMD, targets ambulatory patients aged 3-7. Safety measures and post-marketing studies are in place following reports of liver failure cases.
20 February 2026
Eni Launches Ndungu Full-Field Offshore Angola
Ndungu full-field starts production offshore Angola, boosting output to 60,000 barrels/day. Part of Agogo IWH, it enhances Angola's oil capacity and aligns with low-carbon goals.
20 February 2026
EU Allocates €225M for Advanced Flu Vaccine Development
The EU funds next-gen flu vaccines to enhance protection, speed up development, and improve pandemic readiness through pre-commercial procurement.
20 February 2026
Roche's Giredestrant NDA Accepted by FDA for Advanced Breast Cancer
FDA accepts giredestrant NDA based on phase III data showing reduced disease progression risk in ER-positive breast cancer. Decision expected by December 18, 2026.
19 February 2026
LanzaJet Secures $47M in New Funding, Valued at $650M
Existing investors boost LanzaJet's ATJ technology growth, supporting commercial deployment and securing feedstock supply through a multi-year tolling structure.
News type
New Projects and Expansions
New Projects and Expansions
Project Updates and Milestones
Project Updates and Milestones
Mergers, Acquisitions, and Partnerships
Mergers, Acquisitions, and Partnerships
Innovation and Product Development
Innovation and Product Development
Operational Changes and Investments
Operational Changes and Investments
Sustainability and Environmental Initiatives
Sustainability and Environmental Initiatives
Financial Performance and Strategy
Financial Performance and Strategy
Executive Appointments and Governance Changes
Executive Appointments and Governance Changes
Regulatory and Compliance Updates
Regulatory and Compliance Updates
Workforce and Corporate Social Responsibility (CSR)
Workforce and Corporate Social Responsibility (CSR)
Crisis and Risk Management
Crisis and Risk Management
The right choices in the European chemical industry
Save time with
chemXplore Analytics
Learn more
19 February 2026
Zenyaku's Rituxan Approved for Autoimmune Hemolytic Anemia Treatment
Rituxan gains approval for treating autoimmune hemolytic anemia, targeting B cells to reduce autoantibodies. Effective for warm AIHA, CAD, and PCH, offering an alternative to steroids.
19 February 2026
Asahi Kasei's Thin-Film Hall Elements Earn IEEE Milestone Recognition
Commercialized in 1983, thin-film Hall elements revolutionized magnetic sensors, enhancing electronics and energy efficiency, with over 50 billion units shipped globally.
19 February 2026
Velocys Achieves 30% Cost Reduction in microFTL™ Technology Deployment
Standardisation and delivery efficiencies enhance capital efficiency for Altalto and NovaSAF 1 projects, advancing them toward final engineering and investment decisions.
19 February 2026
Lilly's Omvoh Maintains Steroid-Free Remission in Crohn's Patients for Three Years
Omvoh shows durable efficacy in Crohn's and UC, with low surgery rates and sustained symptom relief over three years, maintaining steroid-free remission in over 90% of patients.
19 February 2026
Carbon Neutral Fuels Chooses Johnson Matthey, Honeywell for UK E-Fuels Project
Project Starling will convert CO2 and water into sustainable aviation fuel, aiming for 25,000 tons annually by 2031, using advanced technologies for significant emissions savings.
19 February 2026
Johnson & Johnson's Rybrevant Faspro™ Shows 56% Response Rate in First-Line Head and Neck Cancer
The OrigAMI-4 study shows amivantamab with immunotherapy offers durable antitumor activity in recurrent/metastatic head and neck cancer, improving outcomes over current treatments.
19 February 2026
BASF Introduces Circalo for Low Carbon Ethanol Production
Circalo connects farmers and ethanol producers to reduce carbon intensity, aligning with Section 45Z, using xarvio tools for data verification and compliance.
19 February 2026
BASF Launches AdBlue GE Using 100% Green Electricity
AdBlue GE is made with renewable electricity, reducing CO2 emissions. It matches conventional AdBlue in quality and performance. Initial launch in Switzerland, with plans for wider European rollout.
19 February 2026
Statkraft's Former Employees Advance Biofuel Tech at Tofte
Statkraft shifts focus to core technologies, transferring biofuel expertise to a new company led by former employees, aiming to commercialize HTL technology for emissions reduction.
19 February 2026
Merck Reports Positive Phase 3 Trial Results for ENFLONSIA in High-Risk Infants and Children
ENFLONSIA shows consistent safety and efficacy in high-risk infants over two RSV seasons, supporting expanded use for children under 2.
19 February 2026
INEOS Secures €300M French Grant to Decarbonise Lavera Site
The investment cuts CO2 by 331,000 tonnes annually, secures jobs, boosts competitiveness, and supports France's industrial and climate goals through electrification and carbon capture.
19 February 2026
Asahi Kasei's Thin-Film Hall Elements Earn IEEE Milestone Recognition
Thin-film Hall elements, launched in 1983, revolutionized magnetic sensors, enhancing electronics and energy efficiency, with over 50 billion units shipped globally.
18 February 2026
Asahi Kasei Pharma Advances AK1960 to Phase I for Refractory Diseases
AK1960, an ETA receptor antagonist, enters Phase I trials for refractory diseases, leveraging Alchemedicine's HiSAP™ platform and partnerships with Calliditas and Veloxis.
18 February 2026
Johnson & Johnson's RYBREVANT FASPRO™ Gains FDA Breakthrough Status for Advanced Head and Neck Cancer
FDA grants Breakthrough Therapy Designation to RYBREVANT FASPRO™ for HPV-unrelated head and neck cancer after platinum-based chemotherapy and PD-1/PD-L1 inhibitor.
18 February 2026
PureCycle and TOPPAN Partner for Sustainable Recycled Packaging Solutions
They developed a snack bar wrapper with 30% recycled content, targeting thermoforming applications to meet regulatory demands without compromising safety or performance.
18 February 2026
Merck and Mayo Clinic Collaborate on AI-Driven Drug Discovery
The collaboration combines clinical data and AI to enhance drug discovery, focusing on gastroenterology, dermatology, and neurology for tailored therapies.
18 February 2026
Lilly's Taltz and Zepbound Show Superior Results in Psoriasis and Obesity Trial
Taltz and Zepbound together improved skin clearance and weight loss in psoriasis patients with obesity, outperforming Taltz alone in a Phase 3b trial.
18 February 2026
Asahi Kasei Pharma Begins Phase I Study of AK1960
AK1960, a selective endothelin A receptor antagonist, shows promise for treating refractory kidney diseases, aligning with R&D strategies for unmet medical needs.
18 February 2026
NEXTCHEM Secures Licensing Deal in China for NX CONSER™ Technologies
The technologies will enable efficient co-production of BDO and DMS, supporting biopolymer production with improved cost, energy efficiency, and sustainability.
17 February 2026
Perstorp Expands Liquid Cooling Solutions for Data Centers
Perstorp introduces Synplate™ and expands Synmerse™ for efficient, safe liquid cooling in data centers, enhancing performance and sustainability.
17 February 2026
Genmab Releases 2025 Annual Report
The report highlights 2025 achievements, financials, and 2026 outlook, including revenue growth, strategic acquisitions, and regulatory approvals.
17 February 2026
Stahl Wins 2025 adiFORMULATOR Award from adidas
Stahl's commitment to safer formulations and ZDHC compliance earns recognition, highlighting its role in advancing sustainable practices in the chemical industry.
17 February 2026
Neste and World Fuel Services Expand SAF Availability at 100+ European Airports
The five-year agreement supports regulatory compliance and boosts SAF supply, leveraging World Fuel's network and Neste's production capabilities.
17 February 2026
Alchemedicine and Asahi Kasei Pharma License Agreement for HiSAP Compounds
Asahi Kasei Pharma gains global rights to develop and commercialize HiSAP compounds, with Alchemedicine receiving up to ¥41.3 billion in payments and royalties.
← Previous
Next →
